Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV , and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC 50 s ranging from ~3 to ~68 μM.
Products | Products > Disease Areas > Infection | Products > Disease Areas > Viral Infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Filovirus
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.